Lancet Regional Health-Europe最新文献

{"title":"Are all ultra-processed foods bad for health?","authors":"Carlos Augusto Monteiro , Leandro F.M. Rezende","doi":"10.1016/j.lanepe.2024.101106","DOIUrl":"10.1016/j.lanepe.2024.101106","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery of IDH-mutated grade 2 glioma: continually setting the bar higher","authors":"Emmanuel Mandonnet","doi":"10.1016/j.lanepe.2024.101099","DOIUrl":"10.1016/j.lanepe.2024.101099","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet transfusion in neonatal intensive care units of 22 European countries: a prospective observational study","authors":"Nina A.M. Houben ,&nbsp;Enrico Lopriore ,&nbsp;Karin Fijnvandraat ,&nbsp;Camila Caram-Deelder ,&nbsp;Marta Aguar Carrascosa ,&nbsp;Alain Beuchée ,&nbsp;Kristin Brække ,&nbsp;Francesco Cardona ,&nbsp;Anne Debeer ,&nbsp;Sara Domingues ,&nbsp;Stefano Ghirardello ,&nbsp;Ruza Grizelj ,&nbsp;Emina Hadžimuratović ,&nbsp;Christian Heiring ,&nbsp;Jana Lozar Krivec ,&nbsp;Jan Malý ,&nbsp;Katarina Matasova ,&nbsp;Carmel Maria Moore ,&nbsp;Tobias Muehlbacher ,&nbsp;Miklos Szabó ,&nbsp;Lorenzo Zanetto","doi":"10.1016/j.lanepe.2024.101086","DOIUrl":"10.1016/j.lanepe.2024.101086","url":null,"abstract":"<div><h3>Background</h3><div>Platelet transfusions are given to preterm infants with severe thrombocytopenia aiming to prevent haemorrhage. The PlaNeT2/MATISSE trial revealed higher rates of mortality and/or major bleeding in preterm infants receiving prophylactic platelet transfusions at a platelet count threshold of 50 × 10⁹/L compared to 25 × 10⁹/L. The extent to which this evidence has been incorporated into clinical practice is unknown, thus we aimed to describe current neonatal platelet transfusion practices in Europe.</div></div><div><h3>Methods</h3><div>We performed a prospective observational study in 64 neonatal intensive care units across 22 European countries between September 2022 and August 2023. Outcome measures included observed transfusion prevalence rates (per country and overall, pooled using a random effects Poisson model), expected rates based on patient-mix (per country, estimated using logistic regression), cumulative incidence of receiving a transfusion by day 28 (with death and discharge considered as competing events), transfusion indications, volumes and infusion rates, platelet count triggers and increment, and adverse effects.</div></div><div><h3>Findings</h3><div>We included 1143 preterm infants, of whom 71 (6.2%, [71/1143]) collectively received 217 transfusions. Overall observed prevalence rate was 0.3 platelet transfusion days per 100 admission days. By day 28, 8.3% (95% CI: 5.5–11.1) of infants received a transfusion. Most transfusions were indicated for threshold (74.2%, [161/217]). Pre-transfusion platelet counts were above 25 × 10⁹/L in 33.1% [53/160] of these transfusions. There was significant variability in volume and duration.</div></div><div><h3>Interpretation</h3><div>The restrictive threshold of 25 × 10⁹/L is being integrated into clinical practice. Research is needed to explore existing variation and generate evidence for various aspects including optimal volumes and infusion rates.</div></div><div><h3>Funding</h3><div><span>Sanquin</span>, <span>EBA</span>, and <span>ESPR</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142425114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating health into the European Union Migrant and Asylum Pact: a call to action","authors":"Angelo Farina ,&nbsp;Doris Zjalic ,&nbsp;Federico Fama ,&nbsp;Sara Laura Ferrari ,&nbsp;Andrea Gori ,&nbsp;Mario Raviglione","doi":"10.1016/j.lanepe.2024.101096","DOIUrl":"10.1016/j.lanepe.2024.101096","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study","authors":"Claudia Weiß ,&nbsp;Lena-Luise Becker ,&nbsp;Johannes Friese ,&nbsp;Astrid Blaschek ,&nbsp;Andreas Hahn ,&nbsp;Sabine Illsinger ,&nbsp;Oliver Schwartz ,&nbsp;Günther Bernert ,&nbsp;Maja von der Hagen ,&nbsp;Ralf A. Husain ,&nbsp;Klaus Goldhahn ,&nbsp;Janbernd Kirschner ,&nbsp;Astrid Pechmann ,&nbsp;Marina Flotats-Bastardas ,&nbsp;Gudrun Schreiber ,&nbsp;Ulrike Schara ,&nbsp;Barbara Plecko ,&nbsp;Regina Trollmann ,&nbsp;Veronka Horber ,&nbsp;Ekkehard Wilichowski ,&nbsp;Kristina Probst-Schendzielorz","doi":"10.1016/j.lanepe.2024.101092","DOIUrl":"10.1016/j.lanepe.2024.101092","url":null,"abstract":"<div><h3>Background</h3><div>Real-world data on gene addition therapy (GAT) with onasemnogene abeparvovec (OA), including all age groups and with or without symptoms of the disease before treatment are needed to provide families with evidence-based advice and realistic therapeutic goals. Aim of this study is therefore a population-based analysis of all patients with SMA treated with OA across Germany, Austria and Switzerland (D-A-CH).</div></div><div><h3>Methods</h3><div>This observational study included individuals with Spinal Muscular Atrophy (SMA) treated with OA in 29 specialized neuromuscular centers in the D-A-CH-region. A standardized data set including WHO gross motor milestones, SMA validated motor assessments, need for nutritional and respiratory support, and adverse events was collected using the SMArtCARE registry and the Swiss-Reg-NMD. Outcome data were analyzed using a prespecified statistical analysis plan including potential predictors such as age at GAT, <em>SMN2</em> copy number, past treatment, and symptom status.</div></div><div><h3>Findings</h3><div>343 individuals with SMA (46% male, 54% female) with a mean age at OA of 14.0 months (range 0–90, IQR 20.0 months) were included in the analysis. 79 (23%) patients were clinically presymptomatic at the time of treatment. 172 (50%) patients received <em>SMN2</em> splice-modifying drugs prior to GAT (risdiplam: n = 16, nusinersen: n = 154, both: n = 2). Functional motor improvement correlated with lower age at GAT, with the best motor outcome in those younger than 6 weeks, carrying 3 <em>SMN2</em> copies, and being clinically presymptomatic at time of treatment. The likelihood of requiring ventilation or nutritional support showed a significantly increase with older age at the time of GAT and remained stable thereafter. Pre-treatment had no effect on disease trajectories. Liver-related adverse events occurred significantly less frequently up to 8 months of age. All other adverse events showed an even distribution across all age and weight groups.</div></div><div><h3>Interpretation</h3><div>Overall, motor, respiratory, and nutritional outcome were dependent on timing of GAT and initial symptom status. It was best in presymptomatic children treated within the first six weeks of life, but functional motor scores also increased significantly after treatment in all age groups up to 24 months. Additionally, OA was best tolerated when administered at a young age. Our study therefore highlights the need for SMA newborn screening and immediate treatment to achieve the best possible benefit-risk ratio.</div></div><div><h3>Funding</h3><div>The SMArtCARE and Swiss-Reg-NMD registries are funded by different sources (see acknowledgements).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142425744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of recurrence in early-onset versus late-onset non-metastatic colorectal cancer, 2004–2019: a nationwide cohort study","authors":"Jesper Nors ,&nbsp;Kåre Andersson Gotschalck ,&nbsp;Rune Erichsen ,&nbsp;Claus Lindbjerg Andersen","doi":"10.1016/j.lanepe.2024.101093","DOIUrl":"10.1016/j.lanepe.2024.101093","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of colorectal cancer (CRC) in individuals younger than 50 years of age (early-onset CRC) is increasing. Early-onset CRC often present at advanced stage, suggesting a more aggressive cancer course compared to late-onset CRC (age 50–79). This nationwide cohort study estimates the incidence of recurrence following early-onset CRC and late-onset CRC.</div></div><div><h3>Methods</h3><div>The study included all Danish patients &lt;80 years old operated for first-time Union for International Cancer Control (UICC) stage I–III CRC between January 2004 and December 2019. Recurrence status was determined by applying a validated algorithm to individual-level data from nationwide health registries. The 5-year cumulative incidence functions (CIF) of recurrence were reported for early-onset versus late-onset CRC. The difference in time to recurrence was estimated as a time ratio (TR) using an accelerated failure time model.</div></div><div><h3>Findings</h3><div>Among 25,729 CRC patients, 1441 (5.6%) had early-onset CRC. Compared to late-onset CRC, early-onset was associated with advanced disease stages and higher treatment intensity. The 5-year CIF of recurrence was 29% (95% CI: 26%–31%) in early-onset versus 21% (95% CI: 21%–22%) in late-onset CRC. The higher CIF of recurrence for early-onset patients persisted in stage-stratified analysis. Time to recurrence was shorter in early-onset versus late-onset patients with TR = 0.76 (95% CI: 0.67–0.85). The 5-year CIF of recurrence decreased from 2004 to 2019 for both early- and late-onset patients–most prominent for early-onset patients.</div></div><div><h3>Interpretation</h3><div>Early-onset CRC was associated with higher incidence of recurrence at all disease stages. Indicating that the increased risk is not explained by delayed diagnosis. The excess risk diminished from 2004 to 2019, suggesting that early-onset CRC may achieve a similar recurrence risk as late-onset CRC in a contemporary setting.</div></div><div><h3>Funding</h3><div><span>Aarhus University</span>, <span>Novo Nordisk Foundation</span>, <span>Innovation Fund Denmark</span>, and the <span>Danish Cancer Society</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142425743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residential exposure to transportation noise and risk of incident atrial fibrillation: a pooled study of 11 prospective Nordic cohorts","authors":"Jesse D. Thacher ,&nbsp;Nina Roswall ,&nbsp;Mikael Ögren ,&nbsp;Andrei Pyko ,&nbsp;Agneta Åkesson ,&nbsp;Anna Oudin ,&nbsp;Annika Rosengren ,&nbsp;Aslak H. Poulsen ,&nbsp;Charlotta Eriksson ,&nbsp;David Segersson ,&nbsp;Debora Rizzuto ,&nbsp;Emilie Helte ,&nbsp;Eva M. Andersson ,&nbsp;Gunn Marit Aasvang ,&nbsp;Gunnar Engström ,&nbsp;Hrafnhildur Gudjonsdottir ,&nbsp;Jenny Selander ,&nbsp;Jesper H. Christensen ,&nbsp;Jørgen Brandt ,&nbsp;Karin Leander ,&nbsp;Mette Sørensen","doi":"10.1016/j.lanepe.2024.101091","DOIUrl":"10.1016/j.lanepe.2024.101091","url":null,"abstract":"<div><h3>Background</h3><div>Transportation noise has been linked with cardiometabolic outcomes, yet whether it is a risk factor for atrial fibrillation (AF) remains inconclusive. We aimed to assess whether transportation noise was associated with AF in a large, pooled Nordic cohort.</div></div><div><h3>Methods</h3><div>We pooled data from 11 Nordic cohorts, totaling 161,115 participants. Based on address history from five years before baseline until end of follow-up, road, railway, and aircraft noise was estimated at a residential level. Incident AF was ascertained via linkage to nationwide patient registries. Cox proportional hazards models were utilized to estimate associations between running 5-year time-weighted mean transportation noise (L_den) and AF after adjusting for sociodemographics, lifestyle, and air pollution.</div></div><div><h3>Findings</h3><div>We identified 18,939 incident AF cases over a median follow-up of 19.6 years. Road traffic noise was associated with AF, with a hazard ratio (HR) and 95% confidence interval (CI) of 1.02 (1.00–1.04) per 10-dB of 5-year mean time-weighted exposure, which changed to 1.03 (1.01–1.06) when implementing a 53-dB cut-off. In effect modification analyses, the association for road traffic noise and AF appeared strongest in women and overweight and obese participants. Compared to exposures ≤40 dB, aircraft noise of 40.1–50 and &gt; 50 dB were associated with HRs of 1.04 (0.93–1.16) and 1.12 (0.98–1.27), respectively. Railway noise was not associated with AF. We found a HR of 1.19 (1.02–1.40) among people exposed to noise from road (≥45 dB), railway (&gt;40 dB), and aircraft (&gt;40 dB) combined.</div></div><div><h3>Interpretation</h3><div>Road traffic noise, and possibly aircraft noise, may be associated with elevated risk of AF.</div></div><div><h3>Funding</h3><div><span>NordForsk</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modest versus significant excess mortality due to COVID-19 deaths in Europe – authors' reply","authors":"Margherita Pizzato ,&nbsp;Alberto Giovanni Gerli ,&nbsp;Carlo La Vecchia ,&nbsp;Gianfranco Alicandro","doi":"10.1016/j.lanepe.2024.101061","DOIUrl":"10.1016/j.lanepe.2024.101061","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination and birth outcomes of 186,990 women vaccinated before pregnancy: an England-wide cohort study","authors":"Arun K. Suseeladevi ,&nbsp;Rachel Denholm ,&nbsp;Matthew Retford ,&nbsp;Elena Raffetti ,&nbsp;Christy Burden ,&nbsp;Katherine Birchenall ,&nbsp;Victoria Male ,&nbsp;Venetia Walker ,&nbsp;Christopher Tomlinson ,&nbsp;Angela M. Wood ,&nbsp;Luisa Zuccolo ,&nbsp;CVD-COVID-UK/COVID-IMPACT Consortium","doi":"10.1016/j.lanepe.2024.101025","DOIUrl":"10.1016/j.lanepe.2024.101025","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 vaccination in pregnancy is recommended by the World Health Organisation as effective and safe. However, there remains a lack of robust evidence to inform vaccination choices for women of childbearing potential in relation to their future pregnancies. Here we investigated the association between starting a course of COVID-19 vaccination before pregnancy and birth outcomes.</div></div><div><h3>Methods</h3><div>We analysed England-wide linked electronic health records for all pregnancies reaching at least 24 weeks gestation between 25th May 2021 and 28th October 2022. We estimated incidence rates and hazard ratios for birth and pregnancy outcomes by pre-pregnancy COVID-19 vaccination status.</div></div><div><h3>Findings</h3><div>Based on 186,990 women, compared to starting a pregnancy unvaccinated, receiving COVID-19 vaccination within 12 months before pregnancy was associated with lower risks of very and extremely preterm birth and small-for-gestational age in term babies for any vaccine type (adjusted hazard ratio and 95% confidence interval: 0.74 [0.63, 0.88] and 0.94 [0.88, 1.00], respectively), and lower stillbirth risk in those receiving an mRNA vaccine (0.72 [0.52, 1.00]). Incidence of venous thromboembolism during pregnancy was higher amongst women receiving a viral-vector, but not an mRNA vaccine (1.54 [1.10, 2.16] and 1.02 [0.70, 1.50], respectively). Results were generally consistent for different dose regimens and across sensitivity analyses.</div></div><div><h3>Interpretation</h3><div>We found evidence that pregnancies starting within 12 months from a first COVID-19 vaccination, compared to those in unvaccinated women, experienced fewer adverse birth outcomes, overall or in selected subgroups of the general population, accounting for potential confounders. An mRNA vaccine should be preferred to a viral-vector vaccine, to minimise safety issues, but where the latter is the only choice, it is still to be preferred to starting a pregnancy unvaccinated. The venous thromboembolism risk of the viral-vector vaccine was substantially lower compared to that attributable to SARS-CoV-2 infection in pregnancy or to commonly used medications such as hormone replacement therapy and oral contraceptives in the non-pregnant population.</div></div><div><h3>Funding</h3><div>UK <span>National Institute for Health and Care Research</span> (NIHR), <span>UKRI</span> <span>Medical Research Council, UK Research and Innovation</span>, <span>The Alan Turing Institute</span>, <span>Health Data Research UK</span>, the <span>Department of Health and Social Care</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Striking a balance: Europe's green energy ambitions and the environmental impact of lithium","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2024.101090","DOIUrl":"10.1016/j.lanepe.2024.101090","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}